The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial -

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Information type: Randomised controlled trials
Source: The Lancet Diabetes & Endocrinology
Specialities: Cardiovascular system disorders | Diabetes | Stroke
Summary
RCT (n=9,901) reports reduced incidence of stroke, with 158 (3.2%) participants assigned to dulaglutide and 205 (4.1%) of those on placebo suffering a stroke during a median follow-up of 5.4 years (HR 0.76, 95% CI 0.62–0.94; p=0.010).
UKMi comment

In a related editorial, the author summarises outcomes from similar studies involving other glucagon-like peptide 1 (GLP-1) receptor agonists.
Related links: Comment